



## About the Ortho Clinical Diagnostics Franchise

With more than 60 percent of healthcare decisions influenced by diagnostic test results, diagnostics play a major role in healthcare and patient outcomes.<sup>1</sup> In the future, diagnostics will be the common denominator underlying the entire patient care process — from predicting and preventing diseases to guiding therapy and surgical decisions.

Ortho Clinical Diagnostics (OCD) is one of seven franchises that are a part of the medical devices and diagnostics sector of Johnson & Johnson. The OCD franchise is a fully integrated, global business committed to bringing products to market that can help identify illnesses more rapidly, leading to patient care and treatment that will hopefully help to avoid progression to more serious disorders. The OCD franchise is comprised of clinical laboratory tests and systems, instruments and tests for transfusion medicine, biomarkers and cellular therapies.

The franchise is focused on developing and launching high-impact medical tests that will enable diagnostics to take on an even more important role and create an entirely new type of value for the medical system. By developing new, more advanced and precise assays and testing instruments, OCD is helping expand the role of diagnostics to help reduce chronic illnesses worldwide.

Three businesses within the franchise develop and commercialize a variety of products to meet the changing needs of physicians and patients:

**Ortho Clinical Diagnostics** is a leading provider of diagnostic products and services, offering accurate, timely, and cost-effective solutions for screening, diagnosing, monitoring and confirming diseases. The focus is to help hospitals, laboratories and blood centers worldwide deliver results that help patients experience a better quality of life. For nearly 70 years, the company has served the global transfusion medicine community with donor screening and blood typing products. OCD is exploring next generation *in vitro* diagnostic (IVD) technologies for use in Point-of-Care (POC) and near-patient settings (outside the physical facilities of the clinical laboratory).

**Veridex** is dedicated to providing physicians with high-value *in vitro* diagnostic oncology products that may significantly benefit patients through earlier disease detection and may enable personalized strategies to help improve patient management and outcomes. Veridex currently markets two diagnostic tests — CellSearch® and GeneSearch™ — and is researching a number of new prognostic and diagnostic applications.

**Therakos** currently markets the world's only approved integrated systems for extracorporeal photopheresis (ECP). ECP is an innovative cellular therapy that aims to relieve symptoms caused by cutaneous T-cell lymphoma. Therakos pioneered ECP 20 years ago as the first FDA-approved drug-device combination product.

### **Worldwide Locations**

The Ortho Clinical Diagnostics franchise is headquartered in Raritan, NJ, with operations in Rochester, NY, Huntingdon Valley, PA, Pompano Beach, FL and Wales. The franchise has more than 3,500 employees worldwide.

For more information, visit:

Ortho-Clinical Diagnostics, Inc.  
[www.orthoclinical.com](http://www.orthoclinical.com)

Therakos, Inc.  
[www.therakos.com](http://www.therakos.com)

Veridex, LLC  
[www.veridex.com](http://www.veridex.com)

###

---

<sup>1</sup> Source: The Lewin Group, 2005. The Value of Diagnostics: Innovation, Adoption and Diffusion into Health Care.